Basic Leave Cash In – Direct Deposit Option

Eligible employees who elect to cash in basic leave under the Basic Leave Cash-in Program for 2021 will receive a separate payment on Friday, January 22, 2021.


For your convenience, if you are enrolled in payroll direct deposit you will receive this payment by direct deposit, just like your regular paycheck.  This will include any partial deposits to secondary accounts, which are made before your net pay is deposited to your primary account.


If you would like your payment to go to your direct deposit account(s), you do not need to take any action.


However, if the direct deposit option is not convenient for you, or if you do not want your payment deposited into your secondary account(s), you may suppress your direct deposit for this one payment and a live check will be mailed to your home address instead.  Direct deposit will automatically resume to your existing account(s) on the next regular pay date.


To suppress direct deposit of your cash-in payment, please follow the instructions below:

From the Employee Self Service page in PeopleSoft, click on the “Payroll Self Service” tile.


From the Payroll Self Service page, click on the “Suppress Direct Deposit” link on the left-hand side of the page.


On the Suppress Direct Deposit page, read the acknowledgement and click the box next to the statement, “Issue a live check for this payment”.


Click “Submit”.


Sign out of Payroll Self Service and close your browser.


Requests must be submitted by Sunday, January 17, 2021.


Employees receiving cash-in payments who are not enrolled in payroll direct deposit will receive a live check, mailed to their home address.


If you have any questions about suppressing direct deposit for this payment, please contact the Payroll Department at

Posted in Uncategorized | Leave a comment

Vaccine Distribution Update—Sign Up for MyChart!

Sent on behalf of Barbara Wadsworth and Dr. Jon Stallkamp




As you have heard on several of our recent town halls, Main Line Health has been working with state and local health officials to obtain the COVID-19 vaccine for our employees and medical staff. We expect to receive our first shipment of the COVID-19 vaccine in the next two weeks.


While the vaccine will not be mandatory for employees and medical staff at this time, we will make it available to employees and medical staff who wish to be vaccinated, beginning with our emergency department staff and other employees who are providing direct care for COVID-positive patients, including staff in the ICU and on COVID cluster units. Ultimately, our goal is to ensure every member of the MLH team who is providing patient-facing care receives the vaccine.


Regardless of which tier you are a part of as a result of your role or when you are expected to receive the vaccine, there is one thing you can do now to expedite the vaccination process. All employees and medical staff who wish to be vaccinated will be required to register for a Main Line Health MyChart account, if they have not done so already. You will not be eligible to receive the vaccine until you have an MLH MyChart account.


By opening an MLH MyChart account, you will be able to:

  • Receive notifications when you have been identified as eligible to get the vaccination
  • Schedule your vaccine slots
  • Sign vaccine consents
  • Have a record of the immunization

Signing up for MLH MyChart is easy and can be done at any time. Go to and click on the MLH MyChart link. If you need assistance, please call our 24/7/365 portal help desk at 484.580.1080 or send a message securely using our support form. Please note: You cannot schedule an appointment for your vaccination at this time. An announcement will be made when scheduling is available for you, based on your role.


We understand that you have many questions about the vaccine and the distribution process across our System. We have put together a vaccine workgroup to thoughtfully and efficiently deploy these vaccines, and this group is closely following updates provided by the FDA and CDC. We expect to have more information, pending the issuance of an emergency use authorization (EUA) by these federal agencies, as well as the state.


We do know that, just as so many of you have volunteered to help with screenings, we will rely on our qualified clinicians across the System to help us administer these vaccines. If you are interested in assisting with the administration of these vaccines and you are qualified, please email and a member of the team will follow up with you.


Please know that we will seek to answer your questions and provide you updates about this process as soon as they become available. An FAQ sheet is now available on Wellspring, which we hope will address some questions you may have about the vaccine, employees and medical staff who should and will receive it, and more. This FAQ sheet will be available to you anytime, for reference, and we will keep this updated with relevant information. Additionally, information will continue to be shared in our weekly Town Halls, COVID Daily Updates and MLH To Go.


If you have questions, please email As always, we thank you for your patience, cooperation and support during this time.


Barbara Wadsworth, DNP, RN

Executive Vice President | Chief Operating Officer | Chief Nursing Officer


Jon Stallkamp, MD
Interim Chief Medical Officer

Posted in Uncategorized | Leave a comment

Electrophoresis Lab Update

Effective Dec 8th, 2020 we will switch from Helena electrophoretic system to Sebia electrophoretic system for serum/urine protein electrophoresis, serum/urine immunofixation electrophoresis and hemoglobin electrophoresis. The methodology will remain the same, only instrument will change. As a result of this change, serum protein electrophoresis reference ranges will change to a minor degree. Also, if a patient is being followed for monoclonal protein, quantity of monoclonal spike will be 10% to 20% less with Sebia instrument now than prior to the change.


If there are any questions, please call Dr. Bhagat at 484-476-3521.

Posted in Uncategorized | Leave a comment

SmokeFREE Program

Main Line Health’s FREE six session program to help tobacco users and vapers quit. Click here to view the times and dates to participate via ZOOM.

Posted in Uncategorized | Leave a comment

November LIMR Clinical Research Report

By Donna Loyle, communications manager, LIMR


Research studies with clinical implications for patients with J Wave syndromes, brain metastases, periprosthetic joint infection and femoropopliteal artery lesions were published in peer-reviewed journals by investigators at the Lankenau Institute for Medical Research (LIMR) in November.


New therapeutic approach for J Wave syndromes

Experimental models showed that the natural flavone acacetin may be a promising new therapeutic to treat the life-threatening ventricular arrhythmias knows as the J Wave syndromes, which include Brugada and early repolarization syndromes. LIMR investigators: Charles Antzelevitch, PhD, distinguished professor emeritus, and LIMR research professors Jose Di Diego, MD; Hector Barajas-Martinez, PhD; and Alexander Burashnikov, PhD. The manuscript: “Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes” in PLoS One.


Tighter constraints recommended for HA-WBRT for brain metastases

A phase II clinical trial sought to determine if hippocampal avoidance during whole brain radiotherapy (HA-WBRT) for brain metastases can help to preserve patients’ cognitive function. Results showed a significant relationship between “maximum dose to the bilateral hippocampi and deterioration in short-term memory, even amongst patients who met hippocampal constraints according to the protocol, suggesting that tighter constraints may be beneficial.” LIMR investigator: Albert DeNittis, MD, clinical associate professor. The manuscript: “Steep Dose-response Relationship Between Maximum Hippocampal Dose and Memory Deficits Following Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: A Secondary Analysis of NRG/RTOG 0933” in International Journal of Radiation Oncology, Biology, Physics.


Diagnostic test for PJI showed promising results

In patient studies, the FDA-authorized alpha defensin lateral flow test to detect periprosthetic joint infection (PJI) showed sensitivity and specificity rates of 89.5% and 94.8%, respectively. The study also demonstrated the solid performance of the test to diagnose PJI in the clinic. The test was developed at LIMR by MLH orthopedic surgeon and LIMR clinical assistant professor Carl Deirmengian, MD. The manuscript: “Validation of the Alpha Defensin Lateral Flow Test for Periprosthetic Joint Infection” in The Journal of Bone & Joint Surgery.


Eluvia stent helped patients avoid lesion revascularization

The randomized IMPERIAL clinical trial, in which Main Line Health participated, sought to determine safety and patient outcomes of the Eluvia paclitaxel-eluting nitinol stent vs. the Zilver PTX paclitaxel-coated stent in patients with symptomatic femoropopliteal artery lesions. Two-year follow-up of the study’s patients showed a sustained advantage for Eluvia in avoiding target lesion revascularization. Other results showed no difference in prevalence between the study groups, no flow within the hypoechogenic halo, and no associated adverse events. The IMPERIAL study was an international, 65-site clinical trial that was led by LIMR clinical professor William Gray, MD, System Chief of the Division of Cardiovascular Diseases and Co-Director of the Lankenau Heart Institute. The manuscript: “Two-year efficacy and safety results from the IMPERIAL randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent” in Cardiovascular and Interventional Radiology.

Posted in Uncategorized | Leave a comment

Treatment trial for patients diagnosed with limited-stage small cell lung cancer

By Donna Loyle, communications manager, LIMR


Researchers seeks patients who’ve been diagnosed with limited-stage small cell lung cancer (SCLC) for a clinical trial that is testing treatment with chemotherapy and radiation therapy with the medication Tecenriq® (atezolizumab), or chemotherapy and radiotherapy without it


Atezolizumab is an immunotherapy treatment currently FDA approved to treat certain types of cancer. However, atezolizumab has not yet been approved to treat SCLC.


Each participant in this trial receives three cycles of intravenous chemotherapy over a 21-day period and radiotherapy. One group also receives atezolizumab intravenously on day one or two of each chemotherapy cycle. Cycles repeat every three weeks for one year.


Eligible participants are those with limited stage (Tx, T1-T4, N0-3, M0) SCLC. They must not have been previously treated with an immunotherapy agent.


Study NRG-LU005 is approved for all Main Line Health acute care hospitals. The principal investigators are Tracey Evans, MD, and Albert DeNittis, MD. For more, visit

Posted in Uncategorized | Leave a comment

John Schwarz appointed President of Bryn Mawr Hospital

This e-mail is being sent on behalf of Jack Lynch and Barbara Wadsworth…



Following the announcement of Andi Gilbert’s retirement earlier this year, we began our search for her successor. It gives us great pleasure to announce the appointment of John Schwarz as the new president of Bryn Mawr Hospital. He will assume his new role, effective January 1, 2021. In the coming weeks, John will be working with Andi and other members of the Bryn Mawr Hospital leadership team to ensure a smooth transition.

John is a familiar face and proven executive leader here at Main Line Health. Since joining the Lankenau team in 2013 as Vice President of Administration, John has managed several major initiatives focused on advancing Lankenau Medical Center while assuring alignment with Main Line Health’s strategic imperatives.

Among his achievements are leading the launch and accreditation of Lankenau’s Level II Trauma Center which, in its first, second and third year, achieved clinical outcomes in the top decile. This work has been in tandem and collaboration with Paoli Hospital, our first trauma hospital in the system, both outperforming most trauma facilities in the Commonwealth. John consistently focuses on process improvement work, change management, and revenue enhancement/cost savings that advance Main Line Health’s dedication to safety, quality, equity and affordability. John was instrumental in supporting our Systemwide Performance Excellence initiative. He led the workforce initiative and served on the project management team, playing a critical role in identifying opportunities for displaced employees following the closure of Hahnemann University Hospital.

As an operations and business leader, John brings more than two decades of experience to his role. Prior to joining Main Line Health, he served in executive leadership at Cooper Hospital where he oversaw a six-year, $260 million campus expansion plan and led operations and strategy for the largest academic orthopedic practice in South Jersey. Prior to that, John held roles of increasing responsibility as a senior executive at Tenet Healthcare.

In his new role, John will provide leadership and operational oversight at Bryn Mawr Hospital and will collaborate with executive leaders across Main Line Health. He will partner with physicians, providers and service line leaders to advance Bryn Mawr Hospital’s strategy in the market. John will collaborate with the Bryn Mawr Hospital team to build on their success and continue to achieve exceptional safety, quality, patient care, and patient experience in an equitable, inclusive environment.

John’s forward thinking and engaging leadership style coupled with his knowledge of the System and commitment to excellence make him a tremendous asset to the Main Line Health team, and we are excited to welcome him to this new position to continue the legacy of success at Bryn Mawr Hospital.

Please join us in congratulating John on his new role!

With appreciation,

Jack & Barbara

Posted in Uncategorized | Leave a comment

Virtual event: COVID-19 Translational Research at Lankenau Institute for Medical Research (LIMR)

Join us for the LIMR Round Robin, “COVID-19: Translational Research at LIMR,” 12-1 pm, Wed., Dec. 2.


Learn about LIMR’s discoveries this year regarding coronavirus antibodies, natural products that may help patients, T-antigens, and drug-drug synergy. Also learn about COVID-19 clinical trials available for your patients. Speakers will be LIMR investigators who have pivoted their teams to COVID research. LIMR President and CEO George Prendergast will moderate. CMEs are available for physicians.

Posted in Uncategorized | Leave a comment

Clinical Trials of the Week: Studies of patients diagnosed with heart failure

By Donna Loyle, communications manager, LIMR

Main Line Health is participating in several clinical trials for patients who have been diagnosed with heart failure. Trials are testing new devices and treatment options.

  • LOFT-HF seeks to determine if non-invasive administration of oxygen during sleep can help patients with both heart failure and sleep apnea.


  • Transform-HF is comparing long-term outcomes among heart failure patients treated with torsemide or furosemide.


  • Alt Flow is an early feasibility study of the Edwards transcatheter atrial shunt system for patients with left heart failure.


  • Guide-HF is testing the CardioMEMS HF system, a battery-less pressure sensor implanted in the pulmonary artery.
Posted in Uncategorized | Leave a comment

Medtronic’s Latin Webinar – Healthcare insight in Colorectal Surgery: 11.21.2020 8-11am

Dr. Marks will be a featured presenter and the only colorectal surgeon representing the United States in Medtronic’s Latin American Webinar entitled “Healthcare Insight in Colorectal Surgery:

Better outcomes in Colorectal Surgery – How I do?” where he will be showing how he performs his colorectal surgical expertise through video and discussion.

This is taking place tomorrow, November 21 from 8-11am. Click here to access ZOOM webinar.

Posted in Uncategorized | Leave a comment